435 related articles for article (PubMed ID: 16010439)
1. Increased anticancer activity of the thymidylate synthase inhibitor BGC9331 combined with the topoisomerase I inhibitor SN-38 in human colorectal and breast cancer cells: induction of apoptosis and ROCK cleavage through caspase-3-dependent and -independent mechanisms.
Coudray AM; Louvet C; Kornprobst M; Raymond E; André T; Tournigand C; Faivre S; De Gramont A; Larsen AK; Gespach C
Int J Oncol; 2005 Aug; 27(2):553-61. PubMed ID: 16010439
[TBL] [Abstract][Full Text] [Related]
2. Characterization of a thymidylate synthase (TS)-inducible cell line: a model system for studying sensitivity to TS- and non-TS-targeted chemotherapies.
Longley DB; Ferguson PR; Boyer J; Latif T; Lynch M; Maxwell P; Harkin DP; Johnston PG
Clin Cancer Res; 2001 Nov; 7(11):3533-9. PubMed ID: 11705873
[TBL] [Abstract][Full Text] [Related]
3. Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, with the multitargeted antifolate pemetrexed in non-small-cell lung cancer cells.
Giovannetti E; Lemos C; Tekle C; Smid K; Nannizzi S; Rodriguez JA; Ricciardi S; Danesi R; Giaccone G; Peters GJ
Mol Pharmacol; 2008 Apr; 73(4):1290-300. PubMed ID: 18187583
[TBL] [Abstract][Full Text] [Related]
4. Modulation of both endogenous folates and thymidine enhance the therapeutic efficacy of thymidylate synthase inhibitors.
van der Wilt CL; Backus HH; Smid K; Comijn L; Veerman G; Wouters D; Voorn DA; Priest DG; Bunni MA; Mitchell F; Jackman AL; Jansen G; Peters GJ
Cancer Res; 2001 May; 61(9):3675-81. PubMed ID: 11325838
[TBL] [Abstract][Full Text] [Related]
5. Sequence-dependent administration of raloxifene and 5-fluorouracil/pemetrexed protects against pemetrexed cytotoxicity in human bone marrow.
Das JR; Fryar-Tita EB; Green S; Southerland WM; Bowen D
Anticancer Res; 2007; 27(2):825-33. PubMed ID: 17465208
[TBL] [Abstract][Full Text] [Related]
6. Pemetrexed disodium combined with oxaliplatin, SN38, or 5-fluorouracil, based on the quantitation of drug interactions in human HT29 colon cancer cells.
Raymond E; Louvet C; Tournigand C; Coudray AM; Faivre S; De Gramont A; Gespach C
Int J Oncol; 2002 Aug; 21(2):361-7. PubMed ID: 12118332
[TBL] [Abstract][Full Text] [Related]
7. Differences in the induction of DNA damage, cell cycle arrest, and cell death by 5-fluorouracil and antifolates.
Backus HH; Pinedo HM; Wouters D; Kuiper CM; Jansen G; van Groeningen CJ; Peters GJ
Oncol Res; 2000; 12(5):231-9. PubMed ID: 11417748
[TBL] [Abstract][Full Text] [Related]
8. The role of pemetrexed in the treatment of colorectal cancer.
Hochster H
Semin Oncol; 2002 Dec; 29(6 Suppl 18):54-6. PubMed ID: 12571812
[TBL] [Abstract][Full Text] [Related]
9. Effect of adding the topoisomerase I poison 7-ethyl-10-hydroxycamptothecin (SN-38) to 5-fluorouracil and folinic acid in HCT-8 cells: elevated dTTP pools and enhanced cytotoxicity.
Mullany S; Svingen PA; Kaufmann SH; Erlichman C
Cancer Chemother Pharmacol; 1998; 42(5):391-9. PubMed ID: 9771954
[TBL] [Abstract][Full Text] [Related]
10. Thymidylate synthase inhibition induces p53 dependent and independent cell death.
Backus HH; Wouters D; van der Wilt CL; Kuiper CM; van Groeningen CJ; Pinedo HM; Peters GJ
Adv Exp Med Biol; 2000; 486():303-6. PubMed ID: 11783505
[No Abstract] [Full Text] [Related]
11. Mechanisms of action of FdUMP[10]: metabolite activation and thymidylate synthase inhibition.
Bijnsdorp IV; Comijn EM; Padron JM; Gmeiner WH; Peters GJ
Oncol Rep; 2007 Jul; 18(1):287-91. PubMed ID: 17549381
[TBL] [Abstract][Full Text] [Related]
12. Cellular pharmacology of the combination of the DNA topoisomerase I inhibitor SN-38 and the diaminocyclohexane platinum derivative oxaliplatin.
Zeghari-Squalli N; Raymond E; Cvitkovic E; Goldwasser F
Clin Cancer Res; 1999 May; 5(5):1189-96. PubMed ID: 10353756
[TBL] [Abstract][Full Text] [Related]
13. The schedule-dependent enhanced cytotoxic activity of 7-ethyl-10-hydroxy-camptothecin (SN-38) in combination with Gefitinib (Iressa, ZD1839).
Azzariti A; Xu JM; Porcelli L; Paradiso A
Biochem Pharmacol; 2004 Jul; 68(1):135-44. PubMed ID: 15183125
[TBL] [Abstract][Full Text] [Related]
14. A novel polypyrimidine antitumor agent FdUMP[10] induces thymineless death with topoisomerase I-DNA complexes.
Liao ZY; Sordet O; Zhang HL; Kohlhagen G; Antony S; Gmeiner WH; Pommier Y
Cancer Res; 2005 Jun; 65(11):4844-51. PubMed ID: 15930305
[TBL] [Abstract][Full Text] [Related]
15. Combination of 5-fluorouracil and irinotecan on modulation of thymidylate synthase and topoisomerase I expression and cell cycle regulation in human colon cancer LoVo cells: clinical relevance.
Xu JM; Azzariti A; Tommasi S; Lacalamita R; Colucci G; Johnston PG; Church SW; Paradiso A
Clin Colorectal Cancer; 2002 Nov; 2(3):182-8. PubMed ID: 12482336
[TBL] [Abstract][Full Text] [Related]
16. Biological activity of the multitargeted antifolate, MTA (LY231514), in human cell lines with different resistance mechanisms to antifolate drugs.
Schultz RM; Chen VJ; Bewley JR; Roberts EF; Shih C; Dempsey JA
Semin Oncol; 1999 Apr; 26(2 Suppl 6):68-73. PubMed ID: 10598558
[TBL] [Abstract][Full Text] [Related]
17. Cellular interactions of 5-fluorouracil and the camptothecin analogue CPT-11 (irinotecan) in a human colorectal carcinoma cell line.
Guichard S; Hennebelle I; Bugat R; Canal P
Biochem Pharmacol; 1998 Mar; 55(5):667-76. PubMed ID: 9515577
[TBL] [Abstract][Full Text] [Related]
18. Synergistic interaction between the EGFR tyrosine kinase inhibitor gefitinib ("Iressa") and the DNA topoisomerase I inhibitor CPT-11 (irinotecan) in human colorectal cancer cells.
Koizumi F; Kanzawa F; Ueda Y; Koh Y; Tsukiyama S; Taguchi F; Tamura T; Saijo N; Nishio K
Int J Cancer; 2004 Jan; 108(3):464-72. PubMed ID: 14648715
[TBL] [Abstract][Full Text] [Related]
19. Thymidylate synthase: a critical target for cancer chemotherapy.
Rose MG; Farrell MP; Schmitz JC
Clin Colorectal Cancer; 2002 Feb; 1(4):220-9. PubMed ID: 12450420
[TBL] [Abstract][Full Text] [Related]
20. Pharmacologic inhibition of mTOR antagonizes the cytotoxic activity of pemetrexed in non-small cell lung cancer.
Markova B; Hähnel PS; Kasper S; Herbertz S; Schuler M; Breitenbuecher F
J Cancer Res Clin Oncol; 2012 Apr; 138(4):545-54. PubMed ID: 22203472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
